Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot aims to beat semaglutide for weight loss and diabetes

NCT ID NCT07400107

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests a new once-weekly injection, NNC0487-0111, against the approved drug semaglutide in 1000 adults with overweight or obesity and type 2 diabetes. Participants receive two weekly shots (active drug plus placebo) to see if the new drug is safe and leads to greater weight loss and better blood sugar control. The study is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NNC0487-0111 (a new weekly injection for weight loss and diabetes)
What this could lead to
If it works, this could offer a new, effective weekly treatment option for people with obesity and type 2 diabetes, potentially leading to better weight loss and blood sugar control.
What could go wrong
This is a Phase 3 trial, so it's still being tested for safety and effectiveness. The new drug may not prove better than semaglutide, and side effects are possible. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing informed consent. * Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening. * Haemoglobin A1c (HbA1c) 7-10 percentage (%) (53-86 millimole per mole \[mmol/mol\]) (both inclusive) as measured by the central laboratory at screening. * Treatment with lifestyle intervention, and/or 0-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i), thiazolidinediones, or sulfonylureas (SU) as a single agent or in combination) according to local label. Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) before screening. Key Exclusion Criteria: * Renal impairment with estimated Glomerular Filtration Rate (eGFR) \< 30 milliliter (mL)/ minute (min)/1.73 meter squared (m\^2) (2021 Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula), at screening. * Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8. * Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator. * Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2 Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    120 sites in 14 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • APDP - Associação Protectora dos Diabéticos de Portugal

    Lisbon, 1250-189, Portugal

  • Acibadem City Clinic UMHAT Tokuda EAD, Endocrinology

    Sofia, 1407, Bulgaria

  • Adana Şehir Eğitim ve Araştırma Hastanesi-Endokrinoloji

    Yüreğir/Adana, 1370, Turkey (Türkiye)

  • All India Institute of Medical Sciences (AIIMS)

    New Delhi, 110029, India

  • Alliance CEINV Salud S.A. de C.V.

    Monterrey, Nuevo León, 64020, Mexico

  • Amrita Institute Of Medical Sciences & Research Centre

    Kochi, Kerala, 682041, India

  • Ankara Bilkent Şehir Hastanesi-Dahiliye

    Ankara, 06800, Turkey (Türkiye)

  • Arcturus Healthcare, PLC.

    Troy, Michigan, 48098-6368, United States

  • Arthur Asirvatham hospital,

    Madurai, Tamil Nadu, 625 020, India

  • BR Trials - Ensaios Clínicos e Consultoria Ltda.

    São Paulo, São Paulo, 01236-030, Brazil

  • BSES MG hospital

    Mumbai, Maharashtra, 400058, India

  • Başkent Üniversitesi Adana-Endokrinoloji

    Adana /yüreği̇r, 01240, Turkey (Türkiye)

  • Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.

    Legnica, 59-220, Poland

  • Borbánya Praxis E.Ü. Kft.

    Nyíregyháza, Szabolcs-Szatmar Varmegye, 4405, Hungary

  • Békés Vármegyei Központi Kórház

    Gyula, 5700, Hungary

  • CMI Dr. Pletea Noemi SRL

    Bacau, 600154, Romania

  • CPQuali Pesquisa Clínica Ltda

    São Paulo, São Paulo, 01228-000, Brazil

  • Cabinet Medical Dr Geru SRL

    Timișoara, 300288, Romania

  • Centro Médico CIMEL

    Lanús Este, Buenos Aires, B1824KAJ, Argentina

  • Centro Médico Privado San Vicente Diabetes

    Córdoba, X5006IKK, Argentina

  • Centro de Estudios de Investigación Metabólicos y Cardio

    Ciudad Madero, Tamaulipas, 89440, Mexico

  • Centro de Investigaciones Metabólicas

    Capital Federal, Buenos Aires, C1056ABI, Argentina

  • Centrum Kliniczno-Badawcze J.Brzezicki B.Gornikiewicz-Brzezicka Lekarze sp.p.

    Elblag, 82-300, Poland

  • Centrum Terapii Wspolczesnej - J.M. Jasnorzewska S.K.A.

    Lodz, 90-338, Poland

  • Chellaram Diabetes Institute

    Pune, Maharashtra, 411021, India

  • Clinical Hospital Centre Rijeka_Endocrinology

    Rijeka, 51 000, Croatia

  • Consano Clinical Research, LLC

    Shavano Park, Texas, 78231, United States

  • DCC I- Pleven EOOD Endocrinology

    Pleven, 5801, Bulgaria

  • Debreceni Egyetem

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Diabet Med SRL

    Bucharest, 050913, Romania

  • Diabetes, Thyroid and Endocrine Centre

    Jaipur, Rajasthan, 302006, India

  • Diabetes-Zentrum-Wilhelmsburg GbR

    Hamburg, 21109, Germany

  • Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz

    Lingen, 49808, Germany

  • Diacon Hospital Private Limited

    Bangalore, Karnataka, 560010, India

  • Diamond Clinic sp zoo

    Krakow, 31-559, Poland

  • Diseño y Planeación en Investigación Médica S.C.

    Guadalajara, Jalisco, 44600, Mexico

  • Dr. Tatyana Metalova - AIPSMCE EOOD

    Gotse Delchev, 2900, Bulgaria

  • EKAMED sp. z o.o.

    Lublin, Lublin Voivodeship, 20-718, Poland

  • Elite Clinical Trials

    Blackfoot, Idaho, 83221, United States

  • Encore Medical Research LLC

    Hollywood, Florida, 33024, United States

  • Encore Medical Research of Weston

    Weston, Florida, 33331, United States

  • Endo And Metab Cons

    Rockville, Maryland, 20852, United States

  • Endocrine Research Solutions, Inc

    Roswell, Georgia, 30076, United States

  • Endolife Specialty Hospitals

    Guntur, Andhra Pradesh, 522001, India

  • Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann

    Witten, 58455, Germany

  • Gabinet Lekarski Malgorzata Saryusz-Wolska

    Lodz, 90-132, Poland

  • Gabinety Medyczne MATUSZEK Beata Matyjaszek-Matuszek Prywatna Praktyka Specjalistyczna

    Lublin, Lesser Poland Voivodeship, 20-064, Poland

  • General Hospital Dr. Josip Bencevic_Diabetic department

    Slavonski Brod, 35 000, Croatia

  • Göztepe Prof. Dr.Süleyman Yalçın Şehir Hastanesi- Dahiliye

    Istanbul, 34722, Turkey (Türkiye)

  • Herz- und Diabeteszentrum NRW - Bad Oeynhausen

    Bad Oeynhausen, 32545, Germany

  • Hosp. das Forças Armadas_ Endocrinologia

    Lisbon, 1649-020, Portugal

  • Hospital da Luz Arrabida, S.A.

    Vila Nova de Gaia, 4400-346, Portugal

  • Hospital de Cascais

    Alcabideche, 2755-009, Portugal

  • IPGME&R and SSKM Hospital

    Kolkata, West Bengal, 700020, India

  • Institut für Diabetesforschung Osnabrück

    Osnabrück, 49080, Germany

  • Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila

    Bucharest, Bucharest, 020475, Romania

  • Jothydev's Diabetes & Research Center

    Thriruvananthapuram, 695 032, India

  • King Chulalongkorn Memorial Hospital_Endocrinology

    Bangkok, 10330, Thailand

  • Komáromi Selye János Kórház

    Komárom, Komárom-Esztergom, 2900, Hungary

  • Legeartis Poradnie Specjalistyczne Sp. z o.o.

    Bialystok, Podlaskie Voivodeship, 15-404, Poland

  • Lifecare Hospital and Research Centre

    Bengaluru, Karnataka, 560066, India

  • Linden sp. z o.o. sp. k.

    Krakow, 30-105, Poland

  • Lukmed 2 Sp. z o.o.

    Siedlce, 08-110, Poland

  • MHAT Heart and Brain EAD - Pleven, Endocrinology and Metabolic Diseases

    Pleven, 5800, Bulgaria

  • MHAT Knyaginya Klementina - Sofia EAD

    Sofia, 1233, Bulgaria

  • MHAT Sveta Sofia EOOD, Department of Endocrinology and Metabolic diseases

    Sofia, 1404, Bulgaria

  • MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien

    Fulda, 36037, Germany

  • Marmara Üniversitesi Pendik EAH- Endokrinoloji

    Pendik/istanbul, 34899, Turkey (Türkiye)

  • Medical Centre - Clinic Nova EOOD

    Varna, 9000, Bulgaria

  • Medical Institute of Ministry of interior

    Sofia, 1606, Bulgaria

  • Medical Practice SRL

    Oradea, 410001, Romania

  • Medical centre Zdrave 1 OOD

    Kozloduy, 3320, Bulgaria

  • NIZAM'S Institute of Medical Sciences

    Hyderabad, Telangana, 500082, India

  • NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska

    Bialystok, 15-435, Poland

  • NZOZ Vita-Diabetica Malgorzata Buraczyk

    Bialystok, 15-879, Poland

  • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.

    Ruda Śląska, 41-709, Poland

  • Nirmal Hospital Pvt. Ltd.

    Surat, Gujarat, 395002, India

  • Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.

    Porto Alegre, Rio Grande do Sul, 90430-001, Brazil

  • Opca bolnica Karlovac

    Karlovac, 47000, Croatia

  • Opca bolnica Varazdin_Endocrinology

    Varaždin, 42 000, Croatia

  • Optimal Research Sites

    Orange City, Florida, 32763, United States

  • Poli Cardinal Med Srl

    Reghin, Mureș County, 545300, Romania

  • Poliklinika Medikol Zagreb

    Grad Zagreb, 10000, Croatia

  • Poliklinika SLAVONIJA OSIJEK

    Osijek, 31000, Croatia

  • Poliklinika Solmed

    Zagreb, 10000, Croatia

  • Praxis am Markt Dr. Becker

    Essen, 45355, Germany

  • Prywatna Praktyka Lekarska Anna Chudoba

    Żyrardów, 96-300, Poland

  • Przychodnie Grudziadz Sp. z o. o.

    Grudziądz, Mazovian Voivodeship, 86-300, Poland

  • Rajavithi Hospital_Diabetes and Endocrinology

    Bangkok, 10400, Thailand

  • Rajiv Gandhi Centre for Diabetes and Endocrinology, J.N Medical College, Aligarh Muslim University

    Aligarh, 202002, India

  • Ramathibodi Hospital

    Bangkok, 10400, Thailand

  • SC Nutrilife SRL

    Bucharest, 013764, Romania

  • SMO.MD GmbH - Zentrum für klinische Studien

    Magdeburg, 39120, Germany

  • SMS Medical College & Hospital

    Jaipur, Rajasthan, 302004, India

  • SP ZOZ w Kalwarii Zebrzydowskiej

    Kalwaria Zebrzydowska, 34-130, Poland

  • SSG Hospital, Baroda

    Vadodara, Gujarat, 390001, India

  • Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Szyszko

    Zabrze, 41-800, Poland

  • Selma Medical Associates

    Winchester, Virginia, 22601-3834, United States

  • Serce Sp. z o.o.

    Leszno, 64-100, Poland

  • Shalini Tai Meghe Hospital and Research Center

    Nagpur, Maharashtra, 441110, India

  • Siriraj Hospital

    Bangkok, 10700, Thailand

  • Sivas Cumhuriyet Üniversitesi Hastanesi -Endokrinoloji

    Sivas, 58140, Turkey (Türkiye)

  • Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology

    Krapinske Toplice, 49217, Croatia

  • Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski

    Gorzów Wielkopolski, 66-400, Poland

  • Spital Judetean De Urgenta Satu Mare

    Satu Mare, 440055, Romania

  • Srinagarind Hospital

    Khon Kaen, 40002, Thailand

  • Szpital Czerniakowski Sp. z o.o.

    Warsaw, 00-739, Poland

  • TOTALL Diabetes Hormone Institute

    Indore, Madhya Pradesh, 452010, India

  • ULS Almada-Seixal E.P.E. - Hospital Garcia de Orta

    Almada, 2805-267, Portugal

  • ULS De Braga, E.P.E. - Hospital de Braga

    Braga, 4710-243, Portugal

  • ULS De Matosinhos E.P.E.- Hospital Pedro Hispano

    Senhora Da Hora, Matosinhos, 4464-513, Portugal

  • ULS De São João, E.P.E. - Hospital de São João

    Porto, 4200-319, Portugal

  • UMHAT Pulmed OOD - Pazardzhik, Department of Internal Diseases

    Pazardzhik, 4400, Bulgaria

  • USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology

    Sofia, 1431, Bulgaria

  • Velocity Clin Res, Dallas

    Dallas, Texas, 75230, United States

  • Zentrum fuer klinische Studien Suedbrandenburg GmbH

    Elsterwerda, 04910, Germany

  • ceda - Centrum für Diabetologie und Allgemeinmedizin Pohlheim

    Pohlheim, 35415, Germany

  • i9 Pesquisas Clínicas

    Campinas, São Paulo, 13092-133, Brazil

  • Óbudai Egészségügyi Centrum

    Budapest, Pest County, 1036, Hungary

  • İnönü Üniversitesi Turgut Özal Tıp Merkezi Hastanesi- Endokrinoloji

    Battalgazi / Malatya, 44280, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.